Expo Hub
The changing prostate panorama: 18F-Fluciclovine and its role in biochemically recurrent prostate cancer
About this session
Join Dr. Hollie Lai as she discusses challenges associated with PET/CT imaging in pediatric patients. This hour-long webinar provides an in-depth review of the physiologic uptake in areas that differ from imaging adults, how to identify the differences, and what can be done to improve overall image quality when scanning pediatric patients.
1 / 0
Hollie A. Dr. Lai
Orange, California, USA, CHOC Hospital
Related video sessions
1 / 0
The role of FDG PET/CT in the theranostic era
Join Dr. Daniel Pryma as he takes a deep dive into the history, current uses, and the future of theranostics. Learn more about several FDA-approved theranostic pairs and discover the advantages and disadvantages of using this technology to combat life-threatening diseases.
The changeing prostate panorama
Join Dr. Louis Mazzarelli as he discusses the uses and benefits of 18F Fluciclovine in today’s prostate imaging landscape. Review current practice techniques, pitfalls, and a look at the future for imaging biochemically recurrent prostate cancer.
AXUMIN® (fluciclovine F 18) injection
Indication
Axumin® (fluciclovine F 18) injection is indicated for positron emission tomography (PET) imaging in men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen (PSA) levels following prior treatment.
Important safety information
- Image interpretation errors can occur with Axumin PET imaging. A negative image does not rule out recurrent prostate cancer and a positive image does not confirm its presence. The performance of Axumin seems to be affected by PSA levels. Axumin uptake may occur with other cancers and benign prostatic hypertrophy in primary prostate cancer. Clinical correlation, which may include histopathological evaluation, is recommended.
- Hypersensitivity reactions, including anaphylaxis, may occur in patients who receive Axumin. Emergency resuscitation equipment and personnel should be immediately available.
- Axumin use contributes to a patient's overall long-term cumulative radiation exposure, which is associated with an increased risk of cancer. Safe handling practices should be used to minimize radiation exposure to the patient and health care providers. Adverse reactions were reported in ≤1% of subjects during clinical studies with Axumin. The most common adverse reactions were injection site pain, injection site erythema and dysgeusia.
To report suspected adverse reactions to Axumin, call 1-855-AXUMIN1 (1-855-298-6461) or contact FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Dosage forms and strengths
Injection: supplied as a clear, colorless solution in a 30 mL multiple-dose vial containing 335 to 8200 MBq/mL (9 to 221 mCi/mL) fluciclovine F 18 at calibration time and date.
For full prescribing information, visit www.Axumin.com
1 / 0
The convergence of nuclear medicine and pediatric orthopedic surgery
In pediatrics, young patients may not be able to communicate the exact location and intensity of the pain they’re experiencing. Nuclear medicine physicians are learning how to share visual findings from SPECT/CT with referring orthopedic surgeons, resulting in improved collaboration and outcomes.
The statements by Siemens Healthineers’ customers described herein are based on results that were achieved in the customer’s unique setting. Because there is no “typical” hospital or laboratory and many variables exist (e.g., hospital size, samples mix, case mix, level of IT and/or automation adoption) there can be no guarantee that other customers will achieve the same results.